AEG35156

DRUG7 trials

Sponsors

NCIC Clinical Trials Group, Aegera Therapeutics

Conditions

Advanced CancerCarcinomaCarcinoma, Non-Small-Cell LungHuman Mammary CarcinomaLeukemiaPancreasUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

AEG35156 and Docetaxel in Treating Patients With Solid Tumors

CompletedNCT00357747

NCIC Clinical Trials GroupUnspecified Adult Solid Tumor, Protocol Specific

Start: 2005-06-09End: 2010-06-07Updated: 2023-08-04

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

CompletedNCT00372736

NCIC Clinical Trials GroupUnspecified Adult Solid Tumor, Protocol Specific

Start: 2006-07-27End: 2012-01-06Updated: 2023-08-04

Study of XIAP Antisense for Advanced Cancers

TerminatedNCT00385775

Aegera TherapeuticsAdvanced Cancer

Start: 2006-06-30End: 2008-11-30Target: 30Updated: 2008-08-21

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

TerminatedNCT00557596

Aegera TherapeuticsCarcinoma, Pancreas

Start: 2007-09-30End: 2009-11-30Target: 48Updated: 2009-12-01

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

TerminatedNCT00558922

Aegera TherapeuticsCarcinoma, Non-Small-Cell Lung

Start: 2007-09-30End: 2009-10-31Updated: 2009-07-30

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

TerminatedNCT00558545

Aegera TherapeuticsHuman Mammary Carcinoma

Start: 2007-11-30End: 2009-05-31Target: 61Updated: 2009-12-02

Phase 2

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

TerminatedNCT01018069

Aegera TherapeuticsLeukemia

Start: 2009-11-30End: 2010-10-31Target: 60Updated: 2011-07-13